Roger Seheult, MD of MedCram examines vilobelimab in the treatment of severe COVID with possible applications in the treatment of other diseases. See all Dr. Seheult's videos at: https://www.medcram.com (This video was recorded on May 7th, 2023)
Roger Seheult, MD is the co-founder and lead professor at https://www.medcram.com He is Board Certified in Internal Medicine, Pulmonary Disease, Critical Care, and Sleep Medicine and an Associate Professor at the University of California, Riverside School of Medicine.
The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19 (Clinical and translational science) | https://pubmed.ncbi.nlm.nih.gov/35029045/
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial (Lancet Respir Med) | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451499/pdf/main.pdf
All coronavirus updates are at MedCram.com (including more discussion on delta variant covid, COVID Delta, COVID children, natural immunity COVID 19, and more).
MEDCRAM WORKS WITH MEDICAL PROGRAMS AND HOSPITALS:
MedCram offers group discounts for students and medical programs, hospitals, and other institutions. Contact us at [email protected] if you are interested.
